within Pharmacolibrary.Drugs.ATC.R;

model R03AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 5.0,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Rimiterol is a short-acting beta-2 adrenergic receptor agonist previously used as a bronchodilator in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is not widely used or approved in current clinical practice, having largely been replaced by other beta-2 agonists such as salbutamol.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were not identified in published literature for any population. Reported values are plausible estimates based on similarity to other short-acting beta-2 agonists orally inhaled, such as salbutamol, and available secondary sources.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AC05;
